DOC: HEPATITIS B VIRUS REPLICATION AND INTEGRATION


Chronic infection with hepatitis B virus (HBV) affects 240 million people worldwide and may cause liver disease including hepatocellular carcinoma (HCC). Initially patients have high levels of HBV DNA in their blood, no liver disease and express the e antigen (HBeAg).... Document/File: .pdf, filesize: n/a. Filetype: pdf. Filename: hepatitis-b-virus-replication-and-integration. Title: Hepatitis B virus replication and integration. 2014.

 

File Info:

  • Filesize: N/A
  • Source: gupea_dot_ub_dot_gu_dot_se
  •   Date Archived: 2017-05-28
  •   Author: N/A
 
 
 
 
 

Related Files:

 

  EPIDEMIOLOGY AND PREVENTION OF HEPATITIS B VIRUS INFECTION

... HEPATITIS B IS ONE OF THE MOST COMMON INFECTIOUS DISEASES GLOBALLY. IT HAS BEEN ESTIMATED THAT THERE ARE 350 MILLION CHRONIC HEPATITIS B VIRUS (HBV) CARRIERS WORLDWIDE. THE PREVALENCE OF CHRONIC HBV INFECTION VARIES GEOGRAPHICALLY, FROM HIGH (>8%), INTERMEDIATE (2-7%) TO LOW (<2%) PREVALENCE. ...
  epidemiology-and-prevention-of-hepatitis-b-virus-infection     PDF     2017-05-28  
 

 

  HEPATITIS B VIRUS: EPIDEMIOLOGY AND TRANSMISSION RISKS

... HEPATITIS B VIRUS (HBV) INFECTION IS A SERIOUS AND COMMON INFECTIOUS DISEASE OF THE LIVER, AFFECTING MILLIONS OF PEOPLE THROUGHOUT THE WORLD. THE INCUBATION PERIOD FOR HBV IS 45-180 DAYS, MOST COMMONLY 60-90 DAYS. ...
  hepatitis-b-virus-epidemiology-and-transmission-risks     PDF     2017-05-28  
 

 

  HEPATITIS B VIRUS BIOLOGY

... HEPATITIS B VIRUS (HBV) CAUSES TRANSIENT AND CHRONIC INFECTIONS OF THE LIVER. TRANSIENT INFECTIONS MAY PRODUCE SERIOUS ILLNESS, AND APPROXIMATELY 0.5% TERMINATE WITH FATAL, FULMINANT HEPATITIS. CHRONIC INFECTIONS MAY ALSO HAVE SERIOUS CONSEQUENCES: NEARLY 25% TERMINATE IN UNTREATABLE LIVER CANCER (10). WORLDWIDE DEATHS FROM LIVER CANCER CAUSED BY HBV INFECTION PROBABLY EXCEED ONE MILLION PER YEAR (52, 162). ...
  hepatitis-b-virus-biology     PDF     2017-05-28  
 

 

  A RECOMBINANT VESICULAR STOMATITIS VIRUS EBOLA VACCINE

... THE WORST EBOLA VIRUS DISEASE (EVD) OUTBREAK IN HISTORY HAS RESULTED IN MORE THAN 28,000 CASES AND 11,000 DEATHS. WE PRESENT THE FINAL RESULTS OF TWO PHASE 1 TRIALS OF AN ATTENUATED, REPLICATION-COMPETENT, RECOMBINANT VESICULAR STOMATITIS VIRUS (RVSV)–BASED VACCINE CANDIDATE DESIGNED TO PREVENT EVD. ...
  a-recombinant-vesicular-stomatitis-virus-ebola-vaccine     PDF     2017-05-28  
 

 

  CLINICAL GUIDELINES ON THE MANAGEMENT OF HEPATITIS C

... PATIENTS INFECTED WITH HEPATITIS C VIRUS (HCV) SHOULD BE REFERRED TO A CLINICIAN WITH A PARTICULAR INTEREST IN THE INFECTION. PATIENTS MUST HAVE ACCESS TO ADEQUATE COUNSELLING FROM A HEALTH CARER WITH KNOWLEDGE AND EXPERIENCE OF CHRONIC HCV INFECTION. ALL PATIENTS MUST HAVE ACCESS TO THE APPROPRIATE DIAGNOSTIC AND THERAPEUTIC OPTIONS AVAILABLE IN THE MANAGEMENT OF HCV INFECTION. ...
  clinical-guidelines-on-the-management-of-hepatitis-c     PDF     2017-05-27  
 

 

  HEPATITIS B IMMUNE GLOBULIN

... PREVENTS HEPATITIS B INFECTION INPATIENTS WHO ARE KNOWN TO HAVE BEEN EXPOSED, INCLUDING NEONATES BORN TO HBSAG-POSITIVE WOMEN, BY PROVIDING PASSIVE IMMUNITY. ACTION AN IMMUNE GAMMA-GLOBULIN FRACTION CONTAINING HIGH TITERS OF ANTIBODIES TO THE HEPATITIS B SURFACE ANTIGEN. CONFERS PASSIVE IMMUNITY TO HEPATITIS B INFECTION. THERAPEUTIC EFFECTS: PREVENTION OF HEPATITIS B INFECTION. ...
  hepatitis-b-immune-globulin     PDF     2017-05-27  
 

 

  HEPATITIS B IMMUNE GLOBULIN (HUMAN)

... HEPATITIS B IMMUNE GLOBULIN (HUMAN) — HYPERHEPB® S/D TREATED WITH SOLVENT/DETERGENT IS A COLORLESS TO PALE YELLOW OR PINK STERILE SOLUTION OF HEPATITIS B HYPERIMMUNE IMMUNE GLOBULIN FOR INTRAMUSCULAR ADMINISTRATION; IT IS PRESERVATIVE-FREE AND LATEX-FRE ...
  hepatitis-b-immune-globulin-human     PDF     2017-05-27  
 

 

  DACLATASVIR FOR TREATING CHRONIC HEPATITIS C

... DACLATASVIR IS RECOMMENDED AS AN OPTION FOR TREATING CHRONIC HEPATITIS C IN ADULTS, AS SPECIFIED IN TABLE 1, ONLY IF THE COMPAN Y PROVIDES DACLATASVIR AT THE SAME PRICE OR LOWER THAN THAT AGREED WITH THE COMMERCIAL MEDICINES UNIT. ...
  daclatasvir-for-treating-chronic-hepatitis-c     PDF     2017-05-27  
 

 

  INFLUENZA VIRUS VACCINE, H5N1

... HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE INFLUE NZA VIRUS VACCINE, H5N1, SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR INFLUENZA VIRUS VACCINE, H5N1. ...
  influenza-virus-vaccine-h5n1     PDF     2017-05-28  
 

 

  RELEASE OF NEWCASTLE DISE ASE VIRUS VACCINE FROM CHITOSAN MICROSPHERES

... NEWCASTLE DISEASE VACCINE (NDV)-LOADED CHITOSAN MICROSPHE RES (NDV-CM) WERE PREPARED. STIMULATORY EFFECTS OF THESE NDV-CM ON ANTIBODY RESPONSE COMPARED TO FREE NDV WERE EXAMINED IN VITRO AND IN VIVO. IN VITRO STIMULATION OF MACROPHAGES WITH VIRUS VACCINE RESULTED IN HIGHER NUMBER OF CELLS COMPARED TO SALINE-TREATED CONTROL. ...
  release-of-newcastle-dise-ase-virus-vaccine-from-chitosan-microspheres     PDF     2017-05-28